The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Functional analysis of PARP inhibitors AZD 2281 and BSI-201 in human tumor primary cultures: A comparison of activity and examination of synergy with cytotoxic drugs.
R. A. Nagourney
Employment or Leadership Position - Rational Therapeutics
Consultant or Advisory Role - Rational Therapeutics
Stock Ownership - Rational Therapeutics
K. R. Kenyon
No relevant relationships to disclose
F. R. Francisco
Employment or Leadership Position - Rational Therapeutics
P. J. Bernard
Employment or Leadership Position - Rational Therapeutics
S. S. Evans
Employment or Leadership Position - Rational Therapeutics